ViiV Healthcare has unveiled positive clinical data for two two-drug HIV regimens ay the 22nd International AIDS conference in Amsterdam, showing long-term efficacy and non-inferiority to a current standard of care.
Read More
ViiV Healthcare has filed a single-tablet, two-drug regimen of its dolutegravir and Janssen’s rilpivirine with regulators in both the US and EU.
Read More
ViiV Healthcare has unveiled late-stage data showing that an experimental two-drug regimen of its dolutegravir and Janssen Science’s rilpivirine was comparable in efficacy to three- or four-drug antiretroviral regimens in virologically suppressed patients.
Read More
